The $50 mil will be for a variety of needs, not just testing (clinical research). Recruitment for studies has lagged due to the Covid virus. That may have slowed the enrollment for the AE37/Keytruda combo study. But once that’s advancing hopefully interim if not final analysis gets Merck to fund the larger study. NGIO can best grow in valuation by gaining pharma partnerships. I’m curious to learn about the future check points inhibitor combo study(ies.) Hopefully a research institute or something can also support a study like Mary Crowley Cancer Center did for AE37/GP2. There’s so many things that can happen. And Nasdaq will have them on the right avenue.